MedTrace Logo

Exploratory Study Evaluating the Effects of Dermo-cosmetic RV5026B Applied for 2 Months in Adults With Erythrocouperosis

NCT06824870 · Status: TERMINATED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 28

Last updated 2025-04-08

No results posted yet for this study

Summary

This exploratory study aims to evaluate the effects of the test product RV5026B - ET1732 on erythema, as well as on the sensations of discomfort and relief perceived in subjects with erythrocouperose and associated pityriasis folliculorum.

We wish to evaluate:

* firstly the test product alone in order to quantify the effects on the signs \& symptoms on the entire face,
* then the contribution of the test product in addition to a reference topical treatment.

The test product RV5026B - ET1732 was developed to:

* Reduce redness, even if it has already set in, and help limit its reappearance
* Soothe the sensations of heating and discomfort associated

Conditions

  • Erythrocouperose Associated With Pityriasis Folliculorum of the Face

Interventions

OTHER

RV5026B - ET1732 - Period 1

Period 1 (1 month): The tested product RV5026B - ET1732 will be applied twice a-day on full-face The product sould be applied in sufficient quantity to cover the application area.

DRUG

reference topical product - Period 2

Period 2 (1 month) : the reference topical product, prescribed by the investigator will applied each evening on the whole face.

OTHER

RV5026B - ET1732 - Period 2

Period 2 (1 month) : The tested product RV5026B - ET1732 will be applied twice a-day on randomised half-face. The evening application will be done 15 minutes after the application of the reference treatment. Hands must be washed between the application of the 2 products.

Sponsors & Collaborators

  • Pierre Fabre Dermo Cosmetique

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
SUPPORTIVE_CARE
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-10-20
Primary Completion
2025-02-20
Completion
2025-02-20

Countries

  • Belgium

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06824870 on ClinicalTrials.gov